7 terminated. 7 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 1 | 6 | Terminated 6 |
Follow Neoplasm: new trials by email Literature Review of Neoplasm trials Research Report on Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors SAR444200, Atezolizumab - Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 33 | 2022-09-20 | 2026-01-14 |
| The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial 5-Aminolevulinic acid Hydrochloride - Neoplasm, Skull Base Neoplasm | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2021-09-14 | 2025-07-28 |
| Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors SAR444881, Pembrolizumab, Cetuximab - Cancer, Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 125 | 2021-04-11 | 2026-09-29 |
| Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Isatuximab SAR650984, Atezolizumab - Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 107 | 2018-08-06 | 2023-07-10 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy Topical Phenylephrine Solution - Neoplasm, Oral Mucosa | Phase 1 / Phase 2 | Terminated | University of Wisconsin, Madison | 3 | 2015-05-14 | 2019-12-09 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
Neoplasms (7) · Head and Neck Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Primary Myelofibrosis (1) · Skull Base Neoplasms (1)
Bone Diseases (1) · Bone Marrow Diseases (1) · Bone Neoplasms (1) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoma, T-Cell (1) · Lymphoproliferative Disorders (1)
atezolizumab (2) · Aminolevulinic Acid (1) · Carboplatin (1) · Cetuximab (1) · Ipilimumab (1) · Nivolumab (1) · Pemetrexed (1) · Tetanus Toxoid (1) · isatuximab (1) · pembrolizumab (1)
Sanofi (3) · Asana BioSciences (1) · Bristol-Myers Squibb (1) · Icahn School of Medicine at Mount Sinai (1) · University of Wisconsin, Madison (1)
United States (7) · Canada (4) · Spain (2) · Argentina (1) · Belgium (1) · China (1) · Czechia (1) · Israel (1) · Italy (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Alfred-Marc Iloreta, MD (1) · Margo L. Hoover-Regan (1) · Niranjan Rao, PhD (1)
2017 (1), 2018 (1), 2023 (1)